Markers of in vivo activation of coagulation: Interrelationships change with intensity of oral anticoagulation

American Journal of Clinical Pathology

Volumn 105, Issue 3, 1996, Pages 293-297

  Solymoss, Susan ^a,c   Bovill, Edwin G ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF VERMONT   (United States)

^c ST MARY S HOSPITAL   (Canada)

Author keywords

Antithrombin enzyme complex; Fibrinopeptide A; Oral anticoagulation therapy; Plasmin antiplasmin; Prothrombin fragment 1+2

Indexed keywords

ANTICOAGULANT AGENT; ANTIPLASMIN; ANTITHROMBIN; PLASMIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; FUNCTIONAL ASSESSMENT; HUMAN; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 0029870428     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/105.3.293     Document Type: Article

References (22)

1. Poller L. A simple nomogram for the derivation of international normalized ratios for the standardization of prothrombin time. Thromb Haemost 1988;60:18-20.
2. Loeliger EA. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985;54:155-56.
3. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 1992;102:312S-326S.
4. Millenson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD. Monitoring "mini-intensity" anticoagulation with warfarin: Comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1 +2 levels. Blood 1992;79:2034-2038.
5. Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987;80:1535-1544.
6. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2 fragment and thrombin-antithrombin complex. Blood 1982;59:1086-1097.
7. Pelzer H, Schwartz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with antibody against a synthetic peptide. Thromb Haemost 1991;65:153-159.
8. Nossel HL, Yudelman I, Canfield RE, et al. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974;54:43-53.
9. Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler VP Jr. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976;58:1136-1144.
10. Lau H, Rosenberg R. The isolation and characterization of a specific antibody population directed against the thrombin-antithrombin complex. J Biol Chem 1980;255:5885-5893.
11. Harpel PC. Alpha-2-plasmin inhibitor and alpha-2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzymelinked differential antibody immunosorbent assay. J Clin Invest 1981;68:46-55.
12. Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme linked immunosorbent assay (ELISA) for the measurement of PAP complexes in human plasma: Application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost 1986;56:124-127.
13. Boneu B, Bes G, Pelzer H, Sie P, Boccalon H. D-dimers, thrombinantithrombin III complexes and prothrombin fragments 1 +2: Diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991;65:28-32.
14. Estivals M, Pelzer H, Sie P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1 +2, thrombin-antithrombin III complexes and D - dimers in acute deep vein thrombosis: Effects of heparin treatment. Br J Haematol 1991;78:421-424.
15. Yudelman IM, Nossel HL, Kaplan KL Hirsh J. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood 1978;51:1189-1195.
16. Yudelman I, Greenberg J. Factors affecting fibrinopeptide-A levels in patients with venous thromboembolism during anticoagulant therapy. Blood 1982;59:787-792.
17. Manucci PM, Bottasso B, Tripodi A. Prothrombin fragment 1+2 and intensity of treatment with oral anticoagulants. Thromb Haemost 1991;66:741.
18. Linear regression models for medical data. In: Matthews DE, Farewell VT. Using and understanding medical statistics. Basel: Karger, 1988, pp 124-140.
19. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-1681.
20. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans. Insights gained from studies using markers of the hemostatic system activation. Blood 1987;70:343-350.
21. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants: A prospective study. Thromb Haemost 1994;72:222-226.
22. Van Wersch JWJ, Van Mourik-Alderliesten, Coremans A. Comparison of markers of coagulation activation in patients under oral anticoagulation at different levels. Eur J Clin Chem Clin Biochem 1992;30:461-466.